Drug intelligence / Profile preview

HT-002 (9b3be2)

Development stage: Preclinical
Lead developer: Halo Therapeutics
Modality: Small Molecules

Overview

HT-002 is a small molecule dual agonist of GPR40 (Free fatty acid receptor 1) and GPR120 (Free fatty acid receptor 4) being developed by Halo Therapeutics. It is designed to engage gut-receptor mediated appetite and incretin pathways to promote weight loss. The drug is specifically positioned as a second-line weight loss therapy for obesity. It is currently in the preclinical stage of development, with the pipeline indicating it is undergoing lead optimization and preclinical testing.

Other names: Second line weight loss therapy

Targets

FFAR4 (Free fatty acid receptor 4)FFAR1 (Free fatty acid receptor 1)

Beyond the preview

Go deeper on HT-002 (9b3be2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HT-002 (9b3be2).

Explore the full profile